My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    BEZ235 (NVP-BEZ235, Dactolisib)
    BEZ235 (NVP-BEZ235, Dactolisib)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0101
    CAS #: 915019-65-7 (free base); Purity ≥98%

    Description: Dactolisib (formerly also known as NVP-BEZ235 and BEZ-235) is a novel, potent and dual ATP-competitive inhibitor of PI3K (phosphatidylinositol 3-kinase) and mTOR for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Dactolisib displays potent antitumor efficacy against nonfunctioning pituitary adenomas. It inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell. BEZ235 has shown potential anti-tumor activity both in vitro and in vivo. It inhibited growth of multiple cancer cell lines independently of mutation status in PI3K pathway. In xenograft mice models, it blocked PI3K signaling and showed antitumor activity. Combination study demonstrated that it enhances the efficacy of temozolomide. 

    References: Mol Cancer Ther. 2008 Jul;7(7):1851-63; Ann Oncol. 2012 Sep;23(9):2399-408.

    Related CAS:1028385-32-1 (tosylate)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review

    Molecular Weight (MW)

    469.55

    Formula

    C30H23N5O

    CAS No.

    915019-65-7

    Storage

    -20℃ for 3 years in powder form

    -80℃ for 2 years in solvent

    Solubility (In vitro)

    DMSO: 0.01 mg/mL (0.02 mM)

    Water:<1 mg/mL (slightly soluble or insoluble)

    DMF: 18 mg/mL warming (38.33 mM) 

    Solubility (In vivo)

    NMP+polyethylene glycol 300 (10/90, v/v): 30 mg/mL

    Synonym/Chemical Name

    BEZ235; BEZ 235; BEZ-235; NVP BEZ235; NVP-BEZ-235; NVP-BEZ235; NVP-BEZ 235; 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    Kinase Assay: PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH2-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.

     

    Cell Assay: MOLT-4 and CEM-R cells; The solubility of this compound in DMSO is<10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months; 500 nM, for cell cycle inhibition 200 nM, 16 hours for pRb decrease.

    BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. BEZ235 is an mTORC1/2 catalytic inhibitor.

    In Vivo

    BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies.

    Animal model

    Female Harlan athymic nude mice

    Formulation & Dosage

    NMP/polyethylene glycol 300 (10/90, v/v); 45 mg/kg; oral gavage

    References

    Mol Cancer Ther, 2008, 7(7), 1851-1863.PLoS One, 2011, 6(9), e25132.


    These protocols are for reference only. InvivoChem does not independently validate these methods.


    BEZ235 (NVP-BEZ235, Dactolisib)


    Effect of the dual PI3K/mTOR inhibitor NVP-BEZ235 on 3D organotypic cultures of rat primary NFPA cells.


    BEZ235 (NVP-BEZ235, Dactolisib)


    Expression of DEFB1 in human NFPAs and immortalized gonadotroph cells. Clin Cancer Res. 2015 Jul 15;21(14):3204-15.


    BEZ235 (NVP-BEZ235, Dactolisib)

    Effect of the dual PI3K/mTOR inhibitor NVP-BEZ235 in vivo.


    BEZ235 (NVP-BEZ235, Dactolisib)


    Expression of DEFB1 in human NFPAs and immortalized gonadotroph cells.  2015 Jul 15;21(14):3204-15.


    BEZ235 (NVP-BEZ235, Dactolisib)


    Role of DEFB1 in NET cell lines.  2015 Jul 15;21(14):3204-15.


    BEZ235 (NVP-BEZ235, Dactolisib)


    Expression of Defb1, Tnfrsf10b, and Bcl2a1 in rat pituitary adenoma tissues after NVP-BEZ235 treatment in vivo.  2015 Jul 15;21(14):3204-15.

    BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib)
    BEZ235 (NVP-BEZ235, Dactolisib)


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?